Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 11/20 | 0.65 |
| ▸ | RAC1 | P63000 | 1/20 | 0.48 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.42 |
| ▸ | TRIM58 | Q8NG06 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081897 | 0.80 | TERT (0.65) | TERTDOT1L | |
| SCHEMBL4076919 | 0.79 | TERT (1.00) | TERTDOT1L | |
| SCHEMBL4076905 | 0.79 | TERT (0.55) | TERTRAC1 | |
| SCHEMBL6347593 | 0.79 | TERT (0.53) | TERTRAC1DOT1L | |
| SCHEMBL4077093 | 0.78 | TERT (0.86) | TERTDOT1L | |
| SCHEMBL4077105 | 0.78 | TERT (0.97) | TERTDOT1L | |
| SCHEMBL5630261 | 0.77 | TERT (0.76) | TERTRAC1DOT1L | |
| SCHEMBL4073295 | 0.76 | TERT (0.71) | TERTDOT1L | |
| SCHEMBL4076921 | 0.76 | TERT (0.40) | TERTKDM1ARCOR1TRIM58 | |
| SCHEMBL6765978 | 0.73 | TERT (1.00) | TERTDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887873-B2 | Triazine derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-05-03 | — | — | US | claimed |
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | AVENTIS PHARMA S.A. (FR) | 2003-05-08 | — | — | US | claimed |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | AVENTIS PHARMA S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| US-7482352-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2009-01-27 | — | — | US | disclosed |
| US-6887873-B2 | Triazine derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-05-03 | — | — | US | disclosed |
| US-20050070571-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-03-31 | — | — | US | disclosed |
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | AVENTIS PHARMA S.A. (FR) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | DNASE1L3, SERPINB1, BRDT | TERT 43/4885RAC1 811/4885DOT1L 1150/4885 |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | DPYD, NTPCR, NME1 | TERT 196/4885RAC1 1427/4885DOT1L 1385/4885 |
| US-20050070571-A1 | Chemical derivatives and their application as antitelomerase agents | DPYD, NTPCR, NME1 | TERT 196/4885RAC1 1427/4885DOT1L 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.